Bayer AG: Bidding to Win Merck’s OTC Business Harvard Case Solution & Analysis

Bayer AG: Bidding to Win Merck's OTC Business Case Solution

Soon after sending their finest and last deal to get Merck's Customer Care Department, a selection of "non-prescription" (OTC) items with sales amounting to $2 billion, the Bayer M&A group was offered a possibility to modify their quote since another possible acquirer - most likely Reckitt-Benckiser, a UK based business that had outbid them in a couple of previous acquisition auctions - had actually sent a last-minute deal to Merck. Under the existing terms of the made a proposal JV, Merck would pay Bayer $1 billion in advance for access to their pipeline of drugs and might pay up to another $1.2 billion in likely repayments based on real sales.

This is just an excerpt. This case is about  FINANCE & ACCOUNTING

PUBLICATION DATE: January 13, 2017

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.